Tegaserod is a novel selective serotonin receptor type-4 partial agonist that stimulates gastrointestinal motility.
Tegaserod has proven efficacy in irritable bowel syndrome with constipation in women and in men and women with chronic idiopathic constipation.
The effects on gastric emptying, small bowel transit and colonic transit have not been studied in detail in male and female subjects.
Dr Beglinger and colleagues from Switzerland assessed the effect of gender on gastrointestinal transit with and without tegaserod.
A randomized, placebo-controlled, double-blind, crossover study was performed in 40 healthy subjects, of which 23 were males and 17 female.
| The effect was more apparent in male subjects than in females|
|Neurogastroenterology & Motility|
Each treatment period involved 3 and a half days of bid treatment with either 6 mg tegaserod or an identical placebo.
The investigative team assessed transit parameters by a scintigraphy.
The investigators found that tegaserod significantly accelerated gastric emptying, small bowel and colonic transit times.
The team observed that the effect was more apparent in male subjects than in females.
The most striking prokinetic effects were observed in the upper gastrointestinal tract of the stomach and small intestine.
In both healthy male and female subjects, tegaserod markedly accelerated small intestinal transit.
The investigators also noted that tegaserod induced a significant increase in gastric emptying time and colonic transit.
Dr Beglinger's team concluded, “The results imply that tegaserod is a potent prokinetic agent throughout the gastrointestinal tract in both sexes.”